Linking the Declarations of Helsinki and of Taipei: Critical Challenges of Future-Oriented Research Ethics
- 1National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
- 2Independent Medical Consultant, and Consultant, Pharmaceutical Medicine, Athens, Greece
- 3Consultants in Pharmaceutical Medicine, Dover Heights, Australia
- 4LIF, Stockholm, Sweden
- 5Independent Consultant, Basel, Switzerland
- 6Independent Researcher, Bellagio, Italy
- 7Pfizer Biopharmaceuticals Group, Dublin, Ireland
- 8Craveri Pharma, Buenos Aires, Argentina
- 9Cantonal Ethics Committee, Zurich, Switzerland
- 10Eli Lilly & Co., Lisbon, Portugal
- 11Nippon Medical School, Tokyo, Japan
- 12Ferozsons Laboratories Ltd, Karachi, Pakistan
- 13PPH Plus GmbH & Co. KG, Hochheim am Main, Germany
- 14IFAPP Academy, New York, NY, United States
- 15Semmelweis University, Budapest, Hunbary
A corrigendum on
Linking the Declarations of Helsinki and of Taipei: Critical Challenges of Future-Oriented Research Ethics
by Kurihara, C., Baroutsou, V., Becker, S., Brun, J., Franke-Bray, B., Carlesi, R., Chan, A., Collia, L. F., Kleist, P., Laranjeira, L. F., Matsuyama, K., Naseem, S., Schenk, J., Silva, H., and Kerpel-Fronius, S. (2020). Front. Pharmacol. 11:579714. doi:10.3389/fphar.2020.579714
In the original article, there were errors.
In the abstract, “(Declaration of Taipei)” was deleted; in the 1 Introduction section, “1948, in its second year” was changed to “in its second and third years”; in the 4 Individual Participant Data (IPD) Sharing and Trial Registration Requirement section, parenthesis before and after “Supplementary Material”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Author Contributions
All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.
Conflict of Interest
JB is an employee of LIF; AC is an employee of Pfizer Biopharmaceuticals Group; LC is an employee of Craveri Pharma; LF is an employee of Eli Lilly & Co.; SN is an employee of Ferozsons Laboratories Ltd.; JS is an executive consultant of PPH plus GmbH & Co. KG, Hochheim am Main.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Keywords: research ethics, data science, medicines development, privacy protection, data sharing, declaration of Helsinki, declaration of Taipei
Citation: Kurihara C, Baroutsou V, Becker S, Brun J, Franke-Bray B, Carlesi R, Chan A, Collia LF, Kleist P, Laranjeira LF, Matsuyama K, Naseem S, Schenk J, Silva H and Kerpel-Fronius S (2021) Corrigendum: Linking the Declarations of Helsinki and of Taipei: Critical Challenges of Future-Oriented Research Ethics. Front. Pharmacol. 11:637775. doi: 10.3389/fphar.2020.637775
Received: 04 December 2020; Accepted: 23 December 2020;
Published: 08 February 2021.
Edited and reviewed by:
Joseph O. Fadare, Ekiti State University, NigeriaCopyright © 2021 Kurihara, Baroutsou, Becker, Brun, Franke-Bray, Carlesi, Chan, Collia, Kleist, Laranjeira, Matsuyama, Naseem, Schenk, Silva and Kerpel-Fronius. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Chieko Kurihara, Y2hpZWtvLmt1cmloYXJhQG5pZnR5Lm5lLmpw